ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will host a
conference call and webcast to report its second quarter 2014 financial
results on Thursday, July 31 at 8:30 a.m. ET.
To participate in the conference call, please dial 877-546-5020
(domestic) or 857-244-7552 (international) and reference the access code
41331388. The presentation will be available via a live webcast on the
Investors section of www.acorda.com.
Please log in approximately 5 minutes before the scheduled time of the
presentation to ensure a timely connection.
A replay of the call will be available from 1:30 p.m. ET on July 31,
2014 until midnight on August 7, 2014. To access the replay, please dial
888-286-8010 (domestic) or 617-801-6888 (international) and reference
the access code 97847634. The archived webcast will be available in the
Investor Relations section of the Acorda website at www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company focused
on developing therapies that improve the lives of people with
neurological disorders.
Acorda markets three FDA-approved therapies including: AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve
walking in patients with multiple sclerosis (MS); ZANAFLEX
CAPSULES® (tizanidine hydrochloride) and Zanaflex
tablets, a short-acting drug for the management of spasticity; and QUTENZA®
(capsaicin) 8% Patch, for the management of neuropathic pain associated
with postherpetic neuralgia. AMPYRA is marketed outside the United
States as FAMPYRA® (prolonged-release fampridine tablets) by
Biogen Idec under a licensing agreement from Acorda.
Acorda has one of the leading pipelines in the industry of novel
neurological therapies. The Company is currently developing six
clinical-stage therapies and one preclinical stage therapy that address
a range of disorders including post-stroke deficits, epilepsy, stroke,
peripheral nerve damage, spinal cord injury, neuropathic pain, and heart
failure. For more information, please visit the Company’s website at: www.acorda.com.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including our ability to successfully market and sell Ampyra in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including Plumiaz (our trade name for Diazepam
Nasal Spray), or any other acquired or in-licensed programs; we may not
be able to complete development of, obtain regulatory approval for, or
successfully market Plumiaz or other products under development; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to successfully
market Fampyra outside of the U.S. and our dependence on our
collaboration partner Biogen Idec in connection therewith; competition,
including the impact of generic competition on Zanaflex Capsules
revenues; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; failure to comply with regulatory requirements could
result in adverse action by regulatory agencies; and the ability to
obtain additional financing to support our operations. These and other
risks are described in greater detail in Acorda Therapeutics' filings
with the Securities & Exchange Commission. Acorda may not actually
achieve the goals or plans described in its forward-looking statements,
and investors should not place undue reliance on these statements.
Forward-looking statements made in this release are made only as of the
date hereof, and Acorda disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this release.
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance
with accounting principles generally accepted in the United States
(GAAP), and also certain historical and forward-looking non-GAAP
financial measures. In particular, Acorda has provided income, adjusted
to exclude share-based compensation charges and non-cash taxes. These
non-GAAP financial measures are not an alternative for financial
measures prepared in accordance with GAAP. However, the Company believes
the presentation of these non-GAAP financial measures when viewed in
conjunction with our GAAP results, provide investors with a more
meaningful understanding of our ongoing and projected operating
performance because they exclude non-cash charges and benefits that are
substantially dependent on changes in the market price of our common
stock or relate to tax accounting, and expenses that do not arise from
the ordinary course of our business. The Company believes these non-GAAP
financial measures help indicate underlying trends in the company’s
business and are important in comparing current results with prior
period results and understanding projected operating performance. Also,
management uses these non-GAAP financial measures to establish budgets
and operational goals, and to manage the company’s business and to
evaluate its performance. A reconciliation of the historical non-GAAP
financial results presented in this release to our GAAP financial
results is included in the attached financial statements.
Source: Acorda Therapeutics, Inc.